MRGE - Bibliografia

 

 

  1. Klauser AG, Scindlbeck NE, Muller-Lissner SA. Symptoms in gastro-esophageal reflux disease. Lancet1990;335:205-8.
  2. Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J of gastroenterology1997;92:37-41.
  3. Bontempo I, Piretta L, Corazziari E, Michetti F, Anzini F, Torsoli A. Effects of intraluminal acidification on esophageal motor activity. Gut 1994; 35:884-890.
  4. Pulp SR, Richter JE. Esophageal chest pain. Am Family Phys 1989; 40:101-16.
  5. Scindlbeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA. Three year follow-up of patients with gastro-esophageal reflux. Gut 1992;33:1016-9.
  6. Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am j Gastroenterol 2000; 95:67-71.
  7. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar lined (Barrett's) esophagus.N Eng J Med 1985; 313:857-859.
  8. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Eng J Med 1999; 340: 825-831.
  9. Baldi F, Brancaccio ML, Cappiello R, Ghersi S. Esofago di barrett. In Corinaldesi R, Miglioli M, Vaira D, Stanghellini V, Patologia da reflusso gastroesofageo, Ed Il Pensiero Scientifico, Roma 1997:11-21.
  10. Castell Do. Introduction to pathophysiology of gastro-esophageal reflux. In Castell DO, WU WC, Gastroesophageal reflux: pathogenesis,diagnosis, therapy. New York, Future publishing 1985:3-9.
  11. Gallup Organization National Survey: heartburn across America. Princetown, The Gallup Organization Inc, 1988.
  12. Nebel OT, Fornes MF, Castell DO. Symptomatic GER: incidence and precipitating factors. Am J Dig Sci 1976; 21:953-6.
  13. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastroesophageal reflux disease in adult population . Ann Med 1995; 27:67-70.
  14. Spechler SJ:Epidemiology and natural history of gastro-esophageal reflux. Digestion 1992; 51(1):24-29.
  15. Knill-Jones RP, Card WI, Crean CP, James WB, Spiegelhalter DJ. The symptoms of gastro-esophageal reflux and esophagitis. Scand J Gastroenterol 1984; 19 (106):72-76.
  16. Stanghellini V. La malattia da reflusso gastroesofageo. In: Delle Fave G, Fiocca R, Plebani M, Saggioro A, Savarino V, Stanghellini V, (Eds). Aggiornamento in gastroenterologia per medici di medicina generale. Milano 1996.
  17. Baldi F, et al. Inchiesta GISMAD. Gastroenterol Int 1995;6 (suppl 1):1-6
  18. Locke GR, Talley NJ, Fett SL. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted Country, Minnesota. Gastroenterology 1997; 112:1448-56
  19. Loof L, Gotell P, Elfberg B. The incidence of reflux esophagitis. Scand J Gastroenterol 1993;28:113-118
  20. Jones RH, Hungin APS, Philips J. Gastroesophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995;1:149-154
  21. Robinson M, Earnest D, Maton PN. Frequent heartburn symptoms should not be ignored in subjects who self-treat with antiacids. Gastroenterology 1996; 110:A241
  22. Wright AT, Gray MR, Morris AI. Cost effectiveness of detecting Barrett's cancer. Gut 1996;39: 574-579
  23. Zaninotto G, De Meester TR, Scweitzer W. The lower esophageal sphincter in health and disease. Am J Surg 1988;155:104-11.
  24. Murray J, Du C, Ledlow A, Bates JN,Conklin JL. Nitric oxide: mediator of non adrenergic non cholinergic opossum esophageal muscle. Am J Physiol 1991;261:401-6.
  25. Mittal RK, Mc Callum RW. Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis. Gastroenterology 1988; 96:593-9.
  26. Corazziari E, Bontempo I, Anzini F. Motor activity of the distal esophagus and gastroesophageal reflux. Gut 1984;25:7-13
  27. Kahrilas PJ,Shi G,Manka M, Joehl RJ Increased frequency of transient lower esophageal sphincter relaxation induceed by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000;118:688-695
  28. Sloan S, Kahrilas PJ Impairment of esophageal emptying with hiatal hernia. Gastroenterology 1991;100:596-605
  29. Glise H. Quality of life and cost of therapy in reflux disease. Scand J Gastroenterol 1995;30 (suppl 210):38-42
  30. Glise H. Quality of life assessment in evaluation of laparoscopic Rossetti fundoplication. Surg Endosc 1995;9:183-189
  31. Hunter JG, Trus TL, Branum GD. A physiologic approach to laparoscopic fundoplication for gastroesophageal reflux disease. Ann Surg 1996;223:673-687.
  32. Velanovich V, Vallance SR Gusz JR. Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg 1996;183:217-224
  33. Fullerton S, Wiklund I, Talley N, et al. Patients with upper gastrointestinal symptoms have a poor quality of life regardless of the presence of esophagitis. Presented at DDW Orlando 1999
  34. Mc Dougall NI, Collins JS, Mc Farland RJ. The effect of treating reflux esophagitis with omeprazole on quality of life. Eur J Gastroenterol Epatol 1998;10: 459-464
  35. Lind T, Havelund T, Carlsson R. Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-979
  36. Schindlbeck NE, Klauser AG, Voderholzer WA. Empiric therapy for gastroesophageal reflux disease. Arch Int Med 1995;155: 1080-12
  37. Johnsson F, Weywadr L, Solhaug JH, One week omeprazole treatment in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1998;33:15-20
  38. Brun J, Bengtsson L, Sorngard H. Diagnostic test and treatment of acid related GERD in a general practice population. Gut 1997;41 (suppl 3):A63
  39. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC. Omeprazole as a diagnostic tool in gastro-esophageal reflux disease. Am J Gastroenterol 1997;92:1997-2000
  40. Fass R, Fennerty B, Yalam JM. Evaluation of the "omeprazole test" in patients with typical symptoms of gastroesophageal reflux disease (GERD). Gstroenterology 1997;112:A114
  41. Stene-Larson G,Weberg R, Larsen IF et al. Relationship of overwieght to hiatus haernia and reflux esophagitis. Scand J Gastroenterol 1988; 23:427-32.
  42. Lesi C, Zoni L, Zanna D. Protocolli dietetici nelle patologie gastro-esofagee: consuetudini, realtà, efficacia. In Gentile MG, Aggiornamenti in nutrizione clinica, Ed Il Pensiero Scientifico, Roma 1994, Vol 2:161-166.
  43. De Vault KR, Castell DJ. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Int Med 1995;155:2165-2173
  44. Chiba N, De Gara CJ, Wilkinson JM. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease. A meta-analysis. Gastroenterology 1997;112:1798-1810
  45. Armstrong D. The clinical usefulness of prokinetics agents in gastroesophageal reflux disease. In: Lundel L (Ed). The management of gastroesophageal reflux disease. London: Science Press, 1997:45-54
  46. Wesdorp ICE, Dekker W, Festen HPM. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. Dig Dis Sci 1993;38:2287-93
  47. Simon TJ, Berenson MM, Berlin RG. Randomized, placebo-controlled, comparison of famotidine 20 mg b.d. versus 40 mg b.d. in patients with erosive esophagitis. Aliment Pharmacol Ther 1994;8:71-9
  48. Tytgat GNJ, Nicolai JJ, Reman FC. Efficay of different doses of cimetidine in the treatment of reflux esophagitis. A review of three large, double-blind, controlled trials. Gastroenterology 1990;99:629-634
  49. Johnson N, Boyd E, Mills J. Acute treatment of reflux esophagitis: a multi-centre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther 1989;3:258-266
  50. Geldof H, Hazelhoff B, Otten MH. Two different dose regimens of cisapride in the treatment of reflux esophagitis: a double-blind comparison with ranitidine. Aliment Pharmacol Ther 1993;7:409-15
  51. Van Outryve M, Vanderlinden I, Dedullen G. Dose-response study with cisapride in gastroesophageal reflux disease. Curr Ther Res 1998; 48:408-15
  52. Ramirez B, Richter J. Promotility drugs in the treatment of gastro-esophageal reflux disease. Aliment Pharmacol Ther 1993;7:5-20
  53. Venables TL, et al. Omeprazole 10 milligrams, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32:965-973
  54. Galmiche JP, et al. Treating the symptoms of gastroesophageal reflux disease; a double blind comparison of omeprazole and cisapride. Aliment Phram. Ther 1997;11:765-773
  55. Wilklund I et al. Quality of life during acute and intermittent treatment of gastroesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. Ital J gastroenterol & Hepatol 1998;30:19-27
  56. Dent J, Brun J, Fendrick AM et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44 (suppl 2):S1-S16
  57. McDougall NI, Johnson BT, Collins JJA, et al. Three to 4.5 year prospective study of prognostic indicators in gastroesophageal reflux disease. Scand J Gastroenterol 1998;33:1016-1022.
  58. Johnston BT, Kee F, Collins JSA, et al. Natural history of reflux esophagitis: a 10 year follow- up of its effect on patient symptomatology and quality of life. Gut 1996;38:481-486.
  59. Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N Eng J Med 1995; 333:1106-1110.
  60. Venables TL, Newland RD, Patel AC et al. Maintenance treatment for gastro-esophageal reflux disease. A placebo-controlled evaluation of 10 mgr omeprazole once daily in clinical practice. Scand J Gastroenterol 1997;32:627-632.
  61. Richter JE. Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol 1997;92 (suppl):30s-34s.
  62. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the mamangementof gastroesophageal reflux disease. Am J Gastroenterol 2000; 95:395-407
  63. Tytgat GNJ, Blum AL, Verlinden M. Prognostic factors for relapse and maintenance treatment with cisapride in gastro-esophageal reflux disease. Aliment Pharmacol Ther 1995;9:271-280.
  64. Carlsson R, Galmiche JP, Dent J, et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997;11:473-482).
  65. Lundell L, Backman L, Ekstrom P, et al. Prevention of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991; 26:248-256.
  66. Metz DC, Strader DB, Orbuch M, et al. Use of omeprazole in Zollinger-Ellison syndrome; a prospective nine year study of efficacy and safety. Aliment Pharmacol Ther 1993,7:597-610.
  67. Dent J, Yeomans ND, MacKinnon M, et al. Omeprazole vs ranitidine for prevention of relapse in reflux esophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994;35:590-598.
  68. Bate CM, Richardson PDI. A one year model for the cost-effectiveness of treating reflux. Br J Med Econ 1992; 2:5-11.
  69. Hillman AL. Economic analysis of alternative treatments for persistent gastro-esophageal reflux disease. Scand J Gastroenterol 1994; 29(suppl. 201):98-102).
  70. Lundell L, Backman L, Ekstrom P, et al. Prevention of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991;26:248-256.
  71. Klinkerberg-Knol EC, Nelis F,Dent J, et al Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000; 118:661-669
  72. Nota prescrittiva C.U.F. n° 48, decreto ministeriale del 22/12/2000 relativo alla Legge n° 537 art 8 comma 10 del 24/12/93 e successive modifiche, in vigore dal 24/2/01 pubblicato sul Supp. Ord. della G.U. del 10/1/01.
  73. Urschel JD. Complications of open and laparoscopic antireflux surgery. Am J Surg 1993; 166:68-70
  74. Alexander HC, Hendler RS, Seymour NE, Shires GT. Laparoscopic treatment of gastroesophageal reflux disease. Am J Surg 1997; 63:434-440
  75. Viljakka MT, Luos Tarinen ME, Isolauri JO. Complications of open and laparoscopic antireflux surgery: 32-year audit at a teaching hospital. J Am Coll Surg 1997; 185:446-450.
Last Updated ( Thursday, 23 November 2006 )